Zanzalintinib
Extra-Pancreatic NET (epNET)
ExelixisSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Extra-Pancreatic NET (epNET) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Exelixis | Phase 3 | B |
Bms-907351 Exelixis | Phase 3 | B |
Atezolizumab Exelixis | Phase 3 | B |
PREDNISONE TABLETS Exelixis | Phase 3 | B |
Abiraterone Acetate Exelixis | Phase 3 | B |
Enzalutamide Exelixis | Phase 3 | B |
Same molecule, other indications
Zanzalintinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →